NVP-BGT226 is a small molecule inhibitor of the protein kinase phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), which play critical roles in regulating cell growth, proliferation, and survival. It has shown promise in preclinical studies for its potential to treat various types of cancer.
Chemical name: (S)-2-(4-(4-morpholino-1-(phenylthio)butan-2-yl)pyrido[2,3-d]pyrimidin-7-yl)-2,3-dihydro-1H-inden-1-one Molecular formula: C31H34N6O3S Formula weight: 566.70 g/mol CAS No: 1245537-68-1
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit multiple protein kinases, including PI3K and mTOR, which play a critical role in regulating cell growth, proliferation, and survival. By blocking these proteins, NVP-BGT226 can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of NVP-BGT226 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that NVP-BGT226 can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for NVP-BGT226 involves inhibition of multiple protein kinases, including PI3K and mTOR, which play a critical role in regulating cell growth, proliferation, and survival. By blocking these proteins, NVP-BGT226 can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Clinical studies have shown that NVP-BGT226 has a favorable safety profile, with no evidence of significant toxicity or serious adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with NVP-BGT226 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for NVP-BGT226 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 1-50 mg/day.
In conclusion, NVP-BGT226 is a promising small molecule inhibitor of multiple protein kinases that play a critical role in regulating cell growth, proliferation, and survival. Its ability to regulate cellular processes makes it a potentially powerful tool for treating diseases characterized by uncontrolled cell growth. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound
